Cargando…
Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases
The polyglutamine (polyQ) diseases, such as Huntington’s disease and several types of spinocerebellar ataxias, are a group of inherited neurodegenerative diseases that are caused by an abnormal expansion of the polyQ tract in disease-causative proteins. Proteins with an abnormally expanded polyQ str...
Autores principales: | Takeuchi, Toshihide, Nagai, Yoshitaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664055/ https://www.ncbi.nlm.nih.gov/pubmed/29019918 http://dx.doi.org/10.3390/brainsci7100128 |
Ejemplares similares
-
The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases
por: Popiel, H. Akiko, et al.
Publicado: (2011) -
Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases
por: Minakawa, Eiko N., et al.
Publicado: (2021) -
Misfolding of Proteins with a Polyglutamine Expansion Is Facilitated by
Proteasomal
Chaperones
por: Rousseau, Erwann, et al.
Publicado: (2009) -
Hsp40 Gene Therapy Exerts Therapeutic Effects on Polyglutamine Disease Mice via a Non-Cell Autonomous Mechanism
por: Popiel, H. Akiko, et al.
Publicado: (2012) -
Polyglutamine Induced Misfolding of Huntingtin Exon1 is Modulated by the Flanking Sequences
por: Lakhani, Vinal V., et al.
Publicado: (2010)